Literature DB >> 12023945

Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1).

Simon J MacKenzie1, George S Baillie, Ian McPhee, Carolynn MacKenzie, Rachael Seamons, Theresa McSorley, Jenni Millen, Matthew B Beard, Gino van Heeke, Miles D Houslay.   

Abstract

1. Challenge of COS1 cells with the adenylyl cyclase activator forskolin led to the activation of recombinant PDE4A8, PDE4B1, PDE4C2 and PDE4D5 cAMP-specific phosphodiesterase long isoforms. 2. Forskolin challenge did not activate mutant long PDE4 isoforms where the serine target residue (STR) within the protein kinase A (PKA) consensus phosphorylation site in Upstream Conserved Region 1 (UCR1) was mutated to alanine. 3. The PKA inhibitor, H89, ablated forskolin activation of wild-type long PDE4 isoforms. 4. Activated PKA caused the in vitro phosphorylation of recombinant wild-type long PDE4 isoforms, but not those where the STR was mutated to alanine. 5. An antiserum specific for the phosphorylated form of the STR detected a single immunoreactive band for recombinant long PDE4 isoforms expressed in COS1 cells challenged with forskolin. This was not evident in forskolin-challenged cells treated with H89. Neither was it evident in forskolin-challenged cells expressing long isoforms where the STR had been mutated to alanine. 6. In transfected COS cells challenged with forskolin, only the phosphorylated PDE4D3 long form showed a decrease in mobility in Western blotting analysis. This decreased mobility of PDE4D3 was ablated upon mutation of either of the two serine targets for PKA phosphorylation in this isoform, namely Ser54 in UCR1 and Ser13 in the isoform-specific N-terminal region. 7. Activation by forskolin challenge did not markedly alter the sensitivity of PDE4A8, PDE4B1, PDE4C2 and PDE4D5 to inhibition by rolipram. 8. Long PDE4 isoforms from all four sub-families can be phosphorylated by protein kinase A (PKA). This leads to an increase in their activity and may thus contribute to cellular desensitization processes in cells where these isoforms are selectively expressed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023945      PMCID: PMC1573369          DOI: 10.1038/sj.bjp.0704743

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  60 in total

Review 1.  The molecular biology of cyclic nucleotide phosphodiesterases.

Authors:  M Conti; S L Jin
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1999

2.  Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family.

Authors:  I McPhee; L Pooley; M Lobban; G Bolger; M D Houslay
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

Review 3.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.

Authors:  J A Beavo
Journal:  Physiol Rev       Date:  1995-10       Impact factor: 37.312

4.  Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8.

Authors:  G B Bolger; I McPhee; M D Houslay
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

Review 5.  Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family).

Authors:  V C Manganiello; M Taira; E Degerman; P Belfrage
Journal:  Cell Signal       Date:  1995-07       Impact factor: 4.315

Review 6.  The postsynaptic density: a subcellular anchor for signal transduction enzymes.

Authors:  T M Klauck; J D Scott
Journal:  Cell Signal       Date:  1995-11       Impact factor: 4.315

7.  Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation.

Authors:  C Sette; M Conti
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

8.  Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.

Authors:  R Alvarez; C Sette; D Yang; R M Eglen; R Wilhelm; E R Shelton; M Conti
Journal:  Mol Pharmacol       Date:  1995-10       Impact factor: 4.436

Review 9.  PDE isoenzymes as targets for anti-asthma drugs.

Authors:  C Schudt; H Tenor; A Hatzelmann
Journal:  Eur Respir J       Date:  1995-07       Impact factor: 16.671

10.  Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.

Authors:  M W Verghese; R T McConnell; J M Lenhard; L Hamacher; S L Jin
Journal:  Mol Pharmacol       Date:  1995-06       Impact factor: 4.436

View more
  102 in total

1.  Short-term regulation of PDE4 activity.

Authors:  V Manganiello
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

2.  PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex.

Authors:  Jennifer J Carlisle Michel; Kimberly L Dodge; Wei Wong; Nicole C Mayer; Lorene K Langeberg; John D Scott
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

Review 3.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

4.  Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.

Authors:  Mahomi Kuroiwa; Gretchen L Snyder; Takahide Shuto; Atsuo Fukuda; Yuchio Yanagawa; David R Benavides; Angus C Nairn; James A Bibb; Paul Greengard; Akinori Nishi
Journal:  Psychopharmacology (Berl)       Date:  2011-08-11       Impact factor: 4.530

Review 5.  Regulating cellular cyclic adenosine monophosphate: "Sources," "sinks," and now, "tunable valves".

Authors:  Michael Getz; Padmini Rangamani; Pradipta Ghosh
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2020-04-23

Review 6.  Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.

Authors:  David J Titus; Anthony A Oliva; Nicole M Wilson; Coleen M Atkins
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

7.  Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue.

Authors:  Wito Richter; S-L Catherine Jin; Marco Conti
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

8.  Phosphodiesterase PDE2 activity, increased by isoprenaline, does not reduce β-adrenoceptor-mediated chronotropic and inotropic effects in rat heart.

Authors:  Alejandro Galindo-Tovar; María Luisa Vargas; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-19       Impact factor: 3.000

9.  The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s).

Authors:  Moses Xie; Brigitte Blackman; Colleen Scheitrum; Delphine Mika; Elise Blanchard; Tao Lei; Marco Conti; Wito Richter
Journal:  Biochem J       Date:  2014-05-01       Impact factor: 3.857

10.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.